You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,132,281


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,132,281
Title:Focused radiation for augmenting immune-based therapies against neoplasms
Abstract: An approach combining immune-based therapies with focused radiation, including stereotactic radiation, to treat cancers is disclosed. The use of focused radiation primes the immune system in a similar manner to vaccines to augment immune-based therapies and can counteract the suppressive effects of a tumor. The combination of focused radiation and immune-based therapies, including administration of at least one immunotherapeutic agent, improves survival compared to each therapy alone and can, in some cases, lead to a durable cure. Accordingly, focused radiation can be an adjuvant for immune-based therapies for treating cancers.
Inventor(s): Zeng; Jing (Rockville, MD), Drake; Charles George (Baltimore, MD), Pardoll; Drew M. (Brookeville, MD), Lim; Michael (Reisterstown, MD)
Assignee: The Johns Hopkins University (Baltimore, MD)
Application Number:14/127,597
Patent Claims:1. A method for treating a tumor in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective dose of focused radiation selected from the group consisting of stereotactic radiosurgery and fractionated stereotactic radiosurgery, to treat the tumor in combination with at least one immune checkpoint inhibitor.

2. The method of claim 1, wherein the focused radiation has a radiation source selected from the group consisting of a particle beam (proton), cobalt-60 (photon), and a linear accelerator (x-ray).

3. The method of claim 1, wherein the at least one immune checkpoint inhibitor is one or more monoclonal antibodies.

4. The method of claim 3, wherein the monoclonal antibody is selected from the group consisting of anti-PD-1 antibody, ipilimumab (anti-CTLA-4), anti-B7-H4, anti-B7-H1, anti-LAG3, BTLA, anti-Tim3, anti-B7-DC, anti-CD160, KIR antagonist antibodies, anti-4-1BB, anti-OX40, anti-CD27, and CD40 agonist antibodies.

5. The method of claim 4, further comprising administering at least one adjuvant in combination with the at least one immune checkpoint inhibitor.

6. The method of claim 5, wherein the at least one adjuvant is selected from the group consisting of a cytokine, an interleukin, an interferon, a granulocyte-macrophage colony-stimulating factor (GM-CSF), Bacille Clamette-Guerin (BCG), a keyhole limpet memocyanin (KLH), incomplete Freund's adjuvant (IFA), QS-21, DETOX, and dinitrophenyl.

7. The method of claim 1, wherein the tumor is a tumor associated with a cancer selected from the group consisting of a cancer involving the spine, a lung cancer, a pancreatic cancer, a prostate cancer, a liver cancer, a kidney cancer, a breast cancer, a melanoma, a metastatic orbital tumor, an orbital lymphoma, a benign brain tumor, and combinations thereof.

8. The method of claim 1, further comprising administering to the subject at least one additional therapeutic agent.

9. A method of neoadjuvant therapy for treating cancer in a subject in need of treatment thereof, the method comprising: (a) administering to the subject a therapeutically effective dose of focused radiation selected from the group consisting of stereotactic radiosurgery and fractionated stereotactic radiosurgery, in combination with a therapeutically effective first dose of at least one immune checkpoint inhibitor; (b) performing surgery on the subject to remove at least a portion of a tumor associated with the cancer; and (c) administering to the subject a therapeutically effective dose of focused radiation selected from the group consisting of stereotactic radiosurgery and fractionated stereotactic radiosurgery, in combination with a therapeutically effective second dose of at least one immune checkpoint inhibitor; wherein steps (a), (b), and (c) can be repeated in series or individually as necessary to treat the cancer in the subject.

10. The method of claim 9, further comprising administering to the subject additional chemotherapy and or radiation treatment.

11. The method of claim 10, further comprising administering to the subject adjuvant therapy.

12. The method of claim 11, wherein the at least one adjuvant is selected from the group consisting of a cytokine, an interleukin, an interferon, a granulocyte-macrophage colony-stimulating factor (GM-CSF), Bacille Clamette-Guerin (BCG), a keyhole limpet memocyanin (KLH), incomplete Freund's adjuvant (IFA), QS-21, DETOX, and dinitrophenyl.

13. The method of claim 9, further comprising administering to the subject at least one additional immune checkpoint inhibitor.

14. The method of claim 9, wherein the at least one immune checkpoint inhibitor is selected from one or more monoclonal antibodies.

15. The method of claim 14, wherein the monoclonal antibody is selected from the group consisting of anti-PD-1 antibody, ipilimumab (anti-CTLA-4), anti-B7-H4, anti-B7-H1, anti-LAG3, BTLA, anti-Tim3, anti-B7-DC, anti-CD160, KIR antagonist antibodies, anti-4-1BB, anti-OX40, anti-CD27, and CD40 agonist antibodies.

16. The method of claim 9, wherein the tumor is a tumor associated with a cancer selected from the group consisting of a cancer involving the spine, a lung cancer, a pancreatic cancer, a prostate cancer, a liver cancer, a kidney cancer, a breast cancer, a melanoma, a metastatic orbital tumor, an orbital lymphoma, a benign brain tumor, and combinations thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.